Mol Med Rep· Molecular medicine reports·· 7 days agoScore27
Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)
In brief
This review integrates the molecular mechanisms of renal cell carcinoma (RCC) with phase III clinical evidence, systematically evaluating the therapeutic landscape of VEGF-TKIs, mTOR inhibitors, immune checkpoint inhibitors as monotherapies, and combination regimens including nivolumab plus ipilimumab, pembrolizumab plus axitinib, and lenvatinib plus pembrolizumab.
Source: Mol Med Rep · pubmed.ncbi.nlm.nih.gov